Keurig Dr Pepper (KDP) director receives 6,062 restricted stock units

Rhea-AI Filing Summary

Boston Oray reported acquisition or exercise transactions in this Form 4 filing.

Keurig Dr Pepper Inc. director Boston Oray received a grant of 6,062 restricted stock units of company stock. According to the terms, these units are scheduled to vest on March 4, 2031, subject to certain vesting conditions and exceptions. Each unit represents a contingent right to receive one share of Keurig Dr Pepper common stock when it vests.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boston Oray

(Last) (First) (Middle)

6425 HALL OF FAME LANE

(Street)

FRISCO TX 75034

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Keurig Dr Pepper Inc. [ KDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	03/04/2026		A		6,062		(1)	(1)	Common Stock	6,062	$0	6,062	D

Explanation of Responses:

1. Subject to certain vesting conditions and exceptions, these restricted stock units vest on March 4, 2031. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon vesting.

Remarks:

	/s/ Mark Jackson, attorney in fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Keurig Dr Pepper (KDP) disclose for Boston Oray?

Keurig Dr Pepper reported that director Boston Oray received a grant of 6,062 restricted stock units. These equity awards are a form of compensation that may convert into common shares if vesting conditions are met, aligning the director’s interests with long-term shareholder value.

How many restricted stock units did Boston Oray receive from Keurig Dr Pepper (KDP)?

Boston Oray received 6,062 restricted stock units from Keurig Dr Pepper. This grant increases the director’s equity-linked compensation and represents potential future ownership of 6,062 common shares, provided all vesting conditions are satisfied over the specified timeline ending in 2031.

When do Boston Oray’s Keurig Dr Pepper (KDP) restricted stock units vest?

Boston Oray’s restricted stock units are scheduled to vest on March 4, 2031, subject to certain vesting conditions and exceptions. Vesting means the units convert into common shares, giving the director actual stock ownership if those conditions are fully satisfied by that date.

What does each restricted stock unit represent in the Keurig Dr Pepper (KDP) grant?

Each restricted stock unit in this grant represents a contingent right to receive one share of Keurig Dr Pepper common stock. The units only convert into shares upon vesting, meaning the director’s actual share ownership depends on meeting the stated vesting requirements.

Was Boston Oray’s Keurig Dr Pepper (KDP) equity grant a purchase or an award?

The filing classifies Boston Oray’s transaction as a grant or award acquisition of restricted stock units, not an open-market purchase. The units were awarded at a stated price of zero per unit, reflecting equity-based compensation rather than a cash-funded share purchase.